Translate

Galectin-3 is upregulated in frontotemporal dementia patients with subtype specificity

About UsOur TeamScientific Advisory BoardOur StoriesContact Us
For FamiliesSupport ResourcesResearch ParticipationAbout MAPT FTDNewsletter
For ResearchersResearch ResourcesFDA Listening Session
EventsOur EventsFTD Awareness Week 2025Fundraising

Change Language:

EnglishSpanishFrench
© Cure MAPT FTD is a 501c3 nonprofit
4035 East 18th Avenue, Denver, CO 80220
EIN: 93-2513996
2026 Cure MAPT FTD; all rights reserved
Privacy PolicyCookie Settings